GASC1 Inhibitor Caffeic Acid for Squamous Esophageal Cell Cancer (ESCC)

• Status: Recruiting
• Trial end date: 2022-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Caffeic acid can target inhibit GASC1 (gene amplified in squamous cell carcinoma 1, also known as KDM4C and JMJD2C) expression and GASC1 is confirmed to be a new oncogene in several cancers including esophageal cancer. This study aims to investigate the efficiency and safety of coffeic acid in chinese advanced esophageal squamous cell cancer (ESCC).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The First Affiliated Hospital of Henan University of Science and Technology
• Treatments: Caffeic acid

Criteria

Inclusion Criteria:

1. Chinese

2. esophageal squamous cell cancer

3. stage IV or recurrence disease

4. chemotherapy, or radiotherapy, or palliative care is going on

Exclusion Criteria:

1. PS (performance status): ≥ 3

2. severe hepatic and renal dysfunction

3. hypercoagulability

4. thrombocytosis